Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of August 2026, with a report date of August 24, 2026. The document serves as a transaction notification regarding insider trading activities by a Person Discharging Managerial Responsibilities (PDMR) rather than a financial performance report.
Key Financial Metrics
The filing does not provide corporate financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to specific share transactions:
- Transaction 1 (Aug 20, 2026): Sale of 3,916 ADS at an aggregated price of $52.1400.
- Transaction 2 (Aug 21, 2026): Sale of 40,481 ADS at an aggregated price of $52.1437.
- Total Volume: 44,397 ADS sold across two days.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely discloses the reduction of shareholdings by a specific executive.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a regulatory disclosure of a completed transaction on the New York Stock Exchange (XNYS).
Investor Verification Checklist
- Verify the identity of the seller: Maya Martinez-Davis, President, US.
- Confirm the total number of ADS sold: 44,397 shares.
- Note the transaction dates: August 20 and August 21, 2026.
- Check the execution venue: New York Stock Exchange (XNYS).
- Review the average sale price: Approximately $52.14 per ADS.